Alpha-synuclein picobody - ICB International

Drug Profile

Alpha-synuclein picobody - ICB International

Alternative Names: a-syn-pico

Latest Information Update: 08 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ICB International
  • Developer Centre de recherche du Centre hospitalier universitaire de Sherbrooke; ICB International
  • Class Antibodies
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 07 Jul 2016 Preclinical development is ongoing in USA and Canada
  • 31 Dec 2013 Preclinical trials in Parkinson's disease (Diagnosis) in Canada (Parenteral)
  • 31 Dec 2013 Preclinical trials in Parkinson's disease (Diagnosis) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top